vetklinfo
vetklinfo · FDA/CVM · 27.10.2026

FDA launches risk-based pilot programme for residue analytical methods

The voluntary pilot aims to streamline demonstration of analytical method practicability for new veterinary drugs used in food-producing animals.

Regulatory background

For approval of new animal drugs intended for food-producing species, the FDA requires a practicable method for detecting residues in food. Historically, this has frequently involved time-consuming interlaboratory trials.

Risk-based approach

On 27 October 2026, the Center for Veterinary Medicine (CVM) launched a voluntary Risk-Based Tiered Approach. Methods are assigned to Tier 1 (negligible risk), Tier 2 (low risk) or Tier 3 (moderate risk), depending on their similarity to methods already trusted by FDA or USDA. The demonstration requirements vary accordingly.

One Method Approach

A companion document allows one validated analytical method to support both residue depletion studies and demonstration of practicability where appropriate. It draws on VICH GL49 and FDA Guidance for Industry #3 and may reduce duplicative validation work.

Regulatory status and limitations

Participation is voluntary. The pilot does not replace statutory US food-safety requirements or alter EU residue requirements. FDA estimates potential time savings of approximately two years, but this is not guaranteed for any individual application. The pilot will continue until at least three new animal drugs complete Tier 2 or Tier 3 or until the end of ADUFA VI, if reauthorised, whichever comes first.

Practical implications

Sponsors planning US submissions should evaluate method eligibility and discuss method classification and validation strategy with CVM early in development.

Official primary sources

Editorial status: 30 October 2026. Professional interpretation; official documents take precedence.

← Back to Regulatory Updates